# 4D Molecular Therapeutics Inc. (FDMT)

4D Molecular Therapeutics (FDMT) price hits a 52-week and all-time high, fueled by social media buzz around gene therapy advancements and trial progress. Recent posts highlight positive analyst ratings and ongoing clinical developments.

### About 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc. is a biotechnology company specializing in gene therapies.  
4D Molecular Therapeutics Inc. uses the ticker $FDMT for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights
- 4D Molecular Therapeutics Inc. (FDMT) sentiment is up 67.5% from the previous week.
- 4D Molecular Therapeutics Inc. (FDMT) engagements is up 14.91% from the previous week.
- 4D Molecular Therapeutics Inc. (FDMT) posts created is up 314.29% from the previous week.
- 4D Molecular Therapeutics Inc. Price hit a 52-Week high of $9.70 for the hour
- 4D Molecular Therapeutics Inc. Price hit an all time of $9.70 for the hour
- 4D Molecular Therapeutics Inc. Galaxy Score™ hit a 52-Week high of [--] for the hour
- 4D Molecular Therapeutics Inc. Galaxy Score™ hit an all time of [--] for the hour
- 4D Molecular Therapeutics Inc. entered the top [--] AltRank™ for the first time 

### Price: $9.40
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$fdmt/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$fdmt/time-series/close.tsv)  
FDMT's price has surged to a 52-week high, driven by substantial social media attention and positive sentiment surrounding its gene therapy advancements, particularly the completion of enrollment for the 4FRONT-1 trial. Analyst reiterations and positive outlooks on clinical trials are contributing to this upward momentum.  

24-Hour: 0.43%
7-Day: 4.94%
30-Day: 23.84%

1-Year High: $12.30 on 2025-10-27  
1-Year Low: $3.70 on 2025-06-30  
  
  
### AltRank: [-----]
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$fdmt/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$fdmt/time-series/alt_rank.tsv)  
4D Molecular Therapeutics Inc. (FDMT) is currently AltRank #2,014 based on combined combined social and market metrics
Daily Average: [-----]  
[--] Week: [-----] +823  
1-Year High: [-----] on 2026-01-23  
1-Year Low: [-----] on 2026-01-24  
  
  
### Galaxy Score: [-----]
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$fdmt/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$fdmt/time-series/galaxy_score.tsv)  
Current Value: [-----]  
Daily Average: [--]  
[--] Week: [--] +3  
[--] Month: [--] +4  
[--] Months: [--] [---]  
[--] Year: [--] [---]  
1-Year High: [--] on 2026-02-09  
1-Year Low: [--] on 2025-05-11  
  
  
### Engagements: [---] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$fdmt/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$fdmt/time-series/interactions.tsv)  
Current Value: [---]  
Daily Average: [-----]  
[--] Week: [-----] +15%  
[--] Month: [------] -55%  
[--] Months: [-------] -43%  
[--] Year: [---------] -45%  
1-Year High: [-------] on 2025-08-01  
1-Year Low: [--] on 2025-05-04  

Engagements by network (24h):
Reddit: [--]
YouTube: [--]
X: [---]
TikTok: [--]

  
  
### Mentions: [--] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$fdmt/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$fdmt/time-series/posts_active.tsv)  
Current Value: [--]  
Daily Average: [--]  
[--] Week: [---] +0.76%  
[--] Month: [---] +3,257%  
1-Year High: [---] on 2025-08-04  
1-Year Low: [--] on 2025-04-26  

Mentions by network (24h):
Reddit: [--]
YouTube: [--]
X: [--]
TikTok: [--]

  
  
### Creators: [--] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$fdmt/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$fdmt/time-series/contributors_active.tsv)  
[--] unique social accounts have posts mentioning 4D Molecular Therapeutics Inc. (FDMT) in the last [--] hours which is down 28% from [--] in the previous [--] hours
Daily Average: [--]  
[--] Week: [--] -15%  
[--] Month: [---] +2,133%  
1-Year High: [---] on 2025-08-10  
1-Year Low: [--] on 2025-04-26  

The most influential creators that mention 4D Molecular Therapeutics Inc. in the last [--] hours

| Creator                                            | Rank | Followers | Posts | Engagements |
| -------                                            | ---- | --------- | ----- | ----------- |
| [@Quantumup1](/creator/twitter/Quantumup1)         | [--]    | [-----]     | [--]     | [---]         |
| [@Zellchair](/creator/twitter/Zellchair)           | [--]    | [--]         | [--]     | [--]          |
| [@Tautilas](/creator/twitter/Tautilas)             | [--]    | [-----]     | [--]     | [--]          |
| [@amazing_stocks](/creator/twitter/amazing_stocks) | [--]    | [---]       | [--]     | [--]          |

[View More](/list/creators/$fdmt/100)
  
  
### Sentiment: 100%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$fdmt/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$fdmt/time-series/sentiment.tsv)  
Current Value: 100%  
Daily Average: 82%  
[--] Week: 67% +27%  
[--] Month: 75% +15%  
[--] Months: 75% -25%  
[--] Year: 75% -8%  
1-Year High: 100% on 2025-02-20  
1-Year Low: 25% on 2025-02-18  

Most Supportive Themes:
- Gene Therapy Advancements: (70%) The company is at the forefront of developing innovative gene therapies, showing significant progress and potential in the biotechnology sector.
- Biotechnology Innovation: (20%) $fdmt is recognized for its contributions to biotechnology, with a focus on cutting-edge research and development in genetic treatments.
  
Most Critical Themes:
- Regulatory Hurdles: (5%) Potential challenges in navigating the complex regulatory landscape for gene therapies could impact development timelines and market access.
- Clinical Trial Success Rates: (5%) The success of gene therapy relies heavily on clinical trial outcomes, and any setbacks could significantly affect the company's trajectory.
  
  
  
### Social Dominance: 0.00123%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$fdmt/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/$fdmt/time-series/social_dominance.tsv)  
Current Value: 0.00123%  
Daily Average: 0.00558%  
[--] Week: 0.00117% -0.00893%  
[--] Month: 0.0023% +0.0006999999999999999%  
[--] Months: 0.0023% -0.016%  
[--] Year: 0.0023% -0.0082%  
1-Year High: 0.048% on 2025-08-10  
1-Year Low: 0.0002% on 2025-04-26  
  
  
### Market Dominance: 0.0005429849127677926%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$fdmt/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/$fdmt/time-series/market_dominance.tsv)  
Current Value: 0.0005429849127677926%  
Daily Average: 0%  
1-Year High: 0.021% on 2026-02-06  
1-Year Low: 0.00054% on 2026-02-14  
  
  
### Market Cap: $479,474,016
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$fdmt/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$fdmt/time-series/market_cap.tsv)  
Current Value: $479,474,016  
Daily Average: $444,600,513  
[--] Week: $479,474,016 +5.50%  
[--] Month: $476,923,622 +9.70%  
1-Year High: $500,503,257 on 2026-01-14  
1-Year Low: $388,680,000 on 2026-01-20  

### Top 4D Molecular Therapeutics Inc. Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"$SLV returned +217.12% as the trend continued downward. Our analysts remained focused and waited for price confirmation. Network with high-level traders 👉 $MARA $BBAI $WULF $APLD $CLSK $CORZ $QUBT $FLNC $TEM $CABA $SERV $NNE $TRON $FDMT $PDYN $SEZL http://discord.gg/4BpAVUqkcC http://discord.gg/4BpAVUqkcC"  
[X Link](https://x.com/kyra_liu1/status/2020119374305051080) [@kyra_liu1](/creator/x/kyra_liu1) 2026-02-07T12:56Z [--] followers, [---] engagements


"RBC Capital reiterated $OCUL Outperform-$30 and said We Maintain Our Conviction Into SOL-1 and See Recent Weakness as Buying Opportunity $EYPT $XBI FDMT REGN SRZN RBC Capital additionally said OCUL shares are -28% YTD (vs +2% XBI) with no strong rationale for the downturn beyond investor jitters into the pivotal SOL-1 readout. We think the recent downturn is unfounded as there has been no change to the long-thesis in our view. We maintain conviction in SOL-1 given that: 1) trial readout is within guided timelines; 2) the long-acting TKI class has demonstrated convincing Phase I/II data in"  
[X Link](https://x.com/Quantumup1/status/2019413538993791083) [@Quantumup1](/creator/x/Quantumup1) 2026-02-05T14:11Z [----] followers, 15.4K engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing